Entropy Neurodynamics Limited has released a press release.
All Patients Improve, 50% Achieve 12-Week BED Remission
Earlier from Entropy Neurodynamics
- Appendix 4E and 2026 Annual Report
- Entropy Advances TRP-8803 to US Phase 2 in Depression
- TRP 8803 manufacturing secured for Phase 2/3 advancement
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation